Results 21 to 30 of about 820 (140)

Emicizumab in severe hemophilia A

, 2021
Emicizumab is a recombinant, humanized, bispecific, asymmetric monoclonal antibody that bridges activated factor IX and factor X (FX) and leads to activation of FX, thus mimicking the hemostatic function of activated factor VIII (FVIIIa).
Windyga, Jerzy; Department of Disorders of Hemostasis and Internal Diseases and Department of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
core   +1 more source

Emicizumab for acquired haemophilia A: A case series.

, 2023
BACKGROUND: Emicizumab is approved to prevent bleeding in patients with congenital haemophilia A with or without inhibitors. However, no randomized trials addressed the efficacy of emicizumab in acquired haemophilia A (AHA).
Kathelijne Peerlinck, Vandesande, Johan, Van Laer, Christine, Jacquemin, Marc, Hermans, Cédric, Matthias M. Engelen, Verhamme, Peter, Vanassche, Thomas, Johan De Bent, Engelen, Matthias M., Veerle Labarque, Marc Jacquemin, Cedric Hermans, Johan Vandesande, Peerlinck, Kathelijne, Christine Van Laer, De Bent, Johan, Labarque, Veerle, Peter Verhamme, Engelen, Matthias M, Thomas Vanassche   +20 more
core   +1 more source

Pharmacodynamics Monitoring of Emicizumab in Patients with Hemophilia A

, 2023
Background: Emicizumab is a bispecific antibody mimicking coagulation factor VIII (FVIII) employed to treat patients with hemophilia A (PwHA) regardless of FVIII inhibitor status.
Batista Mesquita Sauvage, Ana Patricia, Rita Marchi Cappelletti, Durual, Stéphane, Gomez, Francisco J, Aliotta, Alessandro, Zermatten, M.G., Francisco J. Gomez, Debora Bertaggia Calderara, Alberio, Lorenzo, Ana Patricia Batista Mesquita Sauvage, Durual, S., Alberio, L., Bertaggia Calderara, D., Casini, A., Lorenzo Alberio, Bertaggia Calderara, Debora, Aliotta, A., Maxime G. Zermatten, Stéphane Durual, Batista Mesquita Sauvage, A.P., Zermatten, Maxime G, Gomez, F.J., Marchi Cappelletti, Rita, Alessandro Aliotta, Casini, Alessandro, Alessandro Casini, Marchi Cappelletti, R.   +26 more
core   +1 more source

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience

Hematology Reports, 2023
Prophylactic treatment with emicizumab has become an important and effective bleeding prevention for people with hemophilia A (PwHA). Perioperative management of PwHA using emicizumab prophylaxis is still challenging due to a lack of experience.
Karla Rener, Saša Anžej Doma, Martina Fink, Helena Podgornik, Irena Preložnik Zupan   +4 more
doaj   +1 more source

Emicizumab: the hemophilia A game changer

Haematologica, 2023
In hemophilia, the unmet needs regarding adherence to prophylaxis and lack of effective longterm prophylaxis regimens, especially in patients with inhibitors, led to the production of emicizumab, the first non-factor medicine for subcutaneous administration in patients with severe and moderate hemophilia A with or without factor VIII inhibitors.
Pedro E. Alcedo Andrade, Pier Mannuccio Mannucci, Craig M. Kessler   +2 more
openaire   +3 more sources

Emicizumab-kxwh: First Global Approval

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Lesley Scott and Esther Kim are salaried employee of Adis/Springer, are responsible for the article content and ...
Lesley J Scott (4995230), Esther S. Kim, Lesley J. Scott, Esther S Kim (5082863)   +3 more
core   +1 more source

Application of systems biology to identify pharmacological mechanisms of thrombotic microangiopathy evoked by combined activated prothrombin complex concentrate and emicizumab

Scientific Reports, 2023
Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy of emicizumab have been demonstrated in several clinical trials.
Raquel Valls, Jonathan Wagg, Ido Paz-Priel, Gabriel Man, Laura Artigas, Georges Jaccard, Mireia Coma, Christophe Schmitt   +7 more
doaj   +1 more source

Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X

Research and Practice in Thrombosis and Haemostasis
Background: Persons with hemophilia A (HA) and inhibitors undergoing emicizumab prophylaxis require bypassing agents when breakthrough bleeding occurs.
Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami   +4 more
doaj   +1 more source

Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro

TH Open, 2018
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with ...
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata, Hidetomo Kitamura, Kaori Fujimoto-Ouchi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Takehisa Kitazawa   +10 more
doaj   +1 more source

Optimization and evaluation of a two-stage chromogenic assay procedure for measurement of emicizumab plasma levels.

PLoS ONE, 2022
Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase complex. Despite functional similarities between FVIIIa and emicizumab, conventional laboratory methods designed for monitoring of FVIII activity are ...
Nasim Shahidi Hamedani, Johannes Oldenburg, Bernd Pötzsch, Jens Müller   +3 more
doaj   +1 more source